HALO Halozyme Therapeutics PE ratio, current and historical analysis

?
Relative Growth: Rel. Growth: 97
Relative Strength: Rel. Strength: 90
Relative Valuation: Rel. Valuation: 27
Relative Profitability: Rel. Profitability: 92

As of Aug 21, 2026, the HALO stock has a P/E ratio of 30.38. The calculation is based on the latest EPS of $3.56 and the stock price of $108.17 per share. An increase of 44% has been observed in the PE ratio compared to its average of 21.1 of the past four quarters.

HALO PE ratio history

How has HALO's PE ratio performed in the past

The mean historical PE ratio of Halozyme Therapeutics over the last nine years is 28.73. The current 30.38 price-to-earnings ratio is 6% more than the historical average. Analyzing the last nine years, HALO's PE ratio reached its highest point in the Sep 2020 quarter at 146, with a price of $26.28 and an EPS of $0.18. The Jun 2025 quarter saw the lowest point at 11.61, with a price of $52.02 and an EPS of $4.48.

Today
30.38
Average
28.73
Median
21.28
Minimum
11.61
Maximum
146

Halozyme Therapeutics PE ratio by year

Maximum annual increase: 173.47% in 2022

Maximum annual decrease: -68.73% in 2021

Year PE ratio PE change Price EPS
2025 25.49 86.6% $67.3 $2.64
2024 13.66 -21.27% $47.81 $3.5
2023 17.35 -54.88% $36.96 $2.13
2022 38.45 173.47% $56.9 $1.48
2021 14.06 -68.73% $40.21 $2.86
2020 44.96 N/A $42.71 $0.95
2019 N/A N/A $17.73 -$0.5
2018 N/A N/A $14.63 -$0.56
2017 44.04 N/A $20.26 $0.46
2016 N/A N/A $9.88 -$0.81
2015 N/A N/A $17.33 -$0.25
2014 N/A N/A $9.65 -$0.56
2013 N/A N/A $14.99 -$0.74
2012 N/A N/A $6.71 -$0.48
2011 N/A N/A $9.51 -$0.19

Halozyme Therapeutics PE ratio by quarter (TTM)

Year PE ratio PE change Price EPS
Jun 2026 21.99 0.73% $78.27 $3.56
Mar 2026 21.83 -14.36% $64.63 $2.96
Dec 2025 25.49 69.93% $67.3 $2.64
Sep 2025 15 29.2% $73.34 $4.89
Jun 2025 11.61 -29.93% $52.02 $4.48
Mar 2025 16.57 21.3% $63.81 $3.85
Dec 2024 13.66 -26.72% $47.81 $3.5
Sep 2024 18.64 -7.08% $57.24 $3.07
Jun 2024 20.06 20.84% $52.36 $2.61
Mar 2024 16.6 -4.32% $40.68 $2.45
Dec 2023 17.35 -13.25% $36.96 $2.13
Sep 2023 20 -3.52% $38.2 $1.91
Jun 2023 20.73 -27.8% $36.07 $1.74
Mar 2023 28.71 -25.33% $38.19 $1.33
Dec 2022 38.45 47.83% $56.9 $1.48

HALO Price vs fair value

How does HALO's price compare to its estimated fair value based on its growth

HALO average PE ratio chart

What is the average PE ratio of HALO for the past years

The current PE ratio of HALO is above its 3, 5 and 10-year averages.

3-year avg
18.23
5-year avg
19.53
10-year avg
28.73
15-year avg
28.73

PE comparison

With a price to earnings (P/E) of 30.38, HALO stands higher than the Healthcare sector and the industry average. Looking at the Healthcare sector average of 24.4, Halozyme Therapeutics's price to earnings (P/E) is 25% higher.

HALO PE vs peers

What is HALO's PE ratio compared to its peers

Frequently asked questions

What is Halozyme Therapeutics's PE ratio?

As of Aug 21, 2026, HALO stock has a price to earnings ratio of 30.38.

What is the 3-year average PE ratio for Halozyme Therapeutics (HALO)?

Over the last 3 years, the average PE ratio for HALO stock is 18.23.

What is the 5-year average PE ratio for Halozyme Therapeutics (HALO)?

Over the last 5 years, the average PE ratio for HALO stock is 19.53.

What is the highest PE ratio for HALO?

Over the last nine years, the quarterly PE ratio reached its highest level at 146 in the Sep 2020 quarter.

How does the current PE ratio for HALO compare to its historical average?

HALO's current price to earnings ratio is 6% above its 9-year historical average.

How is HALO's PE ratio calculated (Halozyme Therapeutics PE ratio formula)?

To determine the P/E ratio, divide the latest stock price by the TTM earnings per share (EPS). As of today (Aug 21, 2026), Halozyme Therapeutics's share price is $108.17. The company's earnings per share for the trailing twelve months (TTM) ending Jun 2026 is $3.56. Therefore, Halozyme Therapeutics's price to earnings ratio for today is 30.38. PE RATIO(30.38) = STOCK PRICE($108.17) / TTM EPS($3.56)

All PE ratio stats are based on quarterly TTM periods, unless otherwise specified.